Table I.
Comparison of baseline characteristics and comorbidities between patients with no/transient type 2 endoleaks vs. patients with persistent/new type 2 endoleaks.
| No/Transient Type II Endoleak |
Persistent/New Type II Endoleak |
||
|---|---|---|---|
| N=1977 | N=390 | P-value | |
| Age (mean in yrs ± SD) | 73± 8.1 | 75±8.1 | <.001 |
| Male | 82% | 79% | 0.157 |
| White race | 97% | 97% | 0.876 |
| Smoking history | 87% | 80% | <.001 |
| Hypertension | 85% | 82% | 0.078 |
| Diabetes Mellitus | 19% | 19% | 0.947 |
| Coronary Artery Disease | 33% | 32% | 0.479 |
| CABG/PCI | 30% | 28% | 0.264 |
| Congestive Heart Failure | 8.4% | 9.2% | 0.613 |
| COPD | 34% | 24% | <.001 |
| Dialysis-dependent | 0.8% | 0.5% | 0.538 |
| Creatinine, >1.8 mg/dL | 5.3% | 2.6% | 0.027 |
| Preoperative Medication | |||
| Aspirin | 74% | 70% | 0.087 |
| Statin | 71% | 69% | 0.344 |
| Plavix | 7.4% | 7.7% | 0.862 |
CABG/PCI, coronary artery bypass graft/percutaneous coronary intervention; COPD, chronic obstructive pulmonary disease;